ADMA Biologics (ADMA) Competitors

Solid Biosciences (NASDAQ:SLDB) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, community ranking, institutional ownership, profitability and earnings.

Does the media refer more to SLDB or ADMA?

In the previous week, Solid Biosciences had 5 more articles in the media than ADMA Biologics. MarketBeat recorded 7 mentions for Solid Biosciences and 2 mentions for ADMA Biologics. Solid Biosciences' average media sentiment score of 1.83 beat ADMA Biologics' score of 0.54 indicating that ADMA Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Solid Biosciences	0 Very Positive mention(s)	3 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
ADMA Biologics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has more risk and volatility, SLDB or ADMA?

Solid Biosciences has a beta of 2.02, indicating that its stock price is 102% more volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.43, indicating that its stock price is 57% less volatile than the S&P 500.

Which has stronger earnings & valuation, SLDB or ADMA?

ADMA Biologics has higher revenue and earnings than Solid Biosciences. ADMA Biologics is trading at a lower price-to-earnings ratio than Solid Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Solid Biosciences	$8.09M	39.19	-$96.01M	-$3.94	-2.10
ADMA Biologics	$258.21M	8.57	-$28.24M	-$0.02	-477.50

Is SLDB or ADMA more profitable?

Solid Biosciences has a net margin of 0.00% compared to Solid Biosciences' net margin of -1.29%. Solid Biosciences' return on equity of 17.24% beat ADMA Biologics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Solid Biosciences	N/A	-55.94%	-44.95%
ADMA Biologics	-1.29%	17.24%	7.38%

Do analysts recommend SLDB or ADMA?

Solid Biosciences currently has a consensus target price of $16.00, suggesting a potential upside of 93.70%. ADMA Biologics has a consensus target price of $10.50, suggesting a potential upside of 9.95%. Given ADMA Biologics' higher possible upside, research analysts plainly believe Solid Biosciences is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Solid Biosciences	0 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.86
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

Does the MarketBeat Community believe in SLDB or ADMA?

ADMA Biologics received 151 more outperform votes than Solid Biosciences when rated by MarketBeat users. Likewise, 71.68% of users gave ADMA Biologics an outperform vote while only 67.55% of users gave Solid Biosciences an outperform vote.

Company	Underperform	Outperform
Solid Biosciences	Outperform Votes 254 67.55%	Underperform Votes 122 32.45%
ADMA Biologics	Outperform Votes 405 71.68%	Underperform Votes 160 28.32%

Do insiders & institutionals believe in SLDB or ADMA?

81.5% of Solid Biosciences shares are held by institutional investors. Comparatively, 75.7% of ADMA Biologics shares are held by institutional investors. 13.6% of Solid Biosciences shares are held by insiders. Comparatively, 3.7% of ADMA Biologics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

ADMA Biologics beats Solid Biosciences on 10 of the 19 factors compared between the two stocks.